Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 21, 2017 – The FDA approved Renflexis (infliximab-abda), Merck and Samsung Bioepsis’ biosimilar to Janssen Biotech’s Remicade® (infliximab).
Download PDF
Return to publications
